Healthcare

March 27, 2015

1

Galderma Announces Positive Outcome of European Decentralised Procedure for Approval of SOOLANTRA® (ivermectin) Cream 10mg/g for Rosacea Patients

Galderma, a global specialty pharmaceutical company focused on dermatology, announced today a positive outcome of the European Decentralised Procedure (DCP) for SOOLANTRA® (ivermectin) Cream 10mg/g for the once-daily topical treatment of inflammatory lesions of papulopustular rosacea in adult patients.

The Medical Products Agency (MPA) in Sweden acted as Reference Member State (RMS) on behalf of 28 EU Member States, which all agreed that SOOLANTRA"...

Continue Reading >

March 24, 2015

2

Dr. Michael’s Dental Clinic Highlights Saving Your Natural Teeth on Root Canal Awareness Week

If you need a root canal, see an endodontist

Root canals don’t cause pain – they relieve it


In support of the Root Canal Awareness Week which runs from March 22-28, 2015, Dr. Yasmin Al-Zoubaidy, Root Canal Specialist at Dr. Michael’s Dental Clinic aims to dispel myths about root canal treatment (RCT) and advocates the special role of the Endodontist on the dental team.


A root canal is a procedure done to treat and save a"......

Continue Reading >

March 24, 2015

3

Cricketing legend Sachin Tendulkar to be the face of Aster Pharmacy; launches 150th outlet

Aster DM Healthcare, a healthcare provider with presence in the Middle East and India, announced legendary cricketer and recipient of the Bharat Ratna Mr. Sachin Tendulkar, as the global face and brand ambassador of the Aster Pharmacy vertical.

Mr. Tendulkar inaugurated the 150th outlet of Aster Pharmacy later in the day which is located at Hamdan Street in Abu Dhabi.


...

Continue Reading >

March 23, 2015

4

New Study Comparing ABThera™ to BVPT, Published in the Annals of Surgery, Demonstrated Reduced 90-Day Mortality

Acelity L.P., Inc. announced today the publication of the results from a single center, prospective, randomized controlled trial comparing the ABThera™ Open Abdomen Negative Pressure Therapy System (ABThera™ OA NPT) to the Barker’s vacuum packing technique (BVPT).1 The investigator-initiated study involved 45 patients with abdominal injury or intra-abdominal sepsis who required temporary abdominal closure following abbreviated laparotomy.


...

Continue Reading >

March 21, 2015

5

Next meeting on health sector situation in South, High Plateaus

A national meeting on the situation of health sector in the provinces of South and High Plateaus will be held on 29th March in Ouargla, Minister of Health, Population and Hospital Reform, Abdelmalek Boudiaf told APS on Thursday on the sidelines of a working visit to Bechar.


This "meeting which will bring together besides the sectors' professionals, representatives of"...

Continue Reading >

March 21, 2015

6

Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials


Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values


...

Continue Reading >

March 21, 2015

7

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

  • Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs. ustekinumab1
  • BI 655066 selectively blocks IL-23, a key protein involved in psoriatic skin inflammation1

For non-UK/non-Canadian media only


For the first time, Boehringer Ingelheim announced Phase II data from its

investigational"...

Continue Reading >

March 21, 2015

8

Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

More patients achieved a PASI-75 response at week 32 than at week 16 for those randomized to OTEZLA at baseline and those switched from etanercept to OTEZLA at week 16


In a post-hoc analysis of PASI-75 at week 16, there was no statistically significant difference between OTEZLA and etanercept


No new safety signals identified through week 32 for OTEZLA


Celgene Corporation"......

Continue Reading >

March 19, 2015

9

Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine

65 percent of patients treated with GED-0301 160 mg once daily for two weeks achieved clinical remission at both day 15 and day 28, versus 10 percent of patients on placebo


72 and 67 percent of patients treated with 160 mg once daily were in clinical remission at day 28 and at day 84, respectively


Overall rates of adverse events and serious adverse events were similar across treatment groups, including placebo


Celgene"......

Continue Reading >

March 18, 2015

10

A thousand billion dinars to build, rehabilitate teaching hospitals

One thousand billion dinars will be devoted for the rehabilitation of 15 teaching hospitals and construction of five other new ones, said Tuesday Lazhar Bounafaâ, director general of the National Agency of Project Management and Equipment of Health Facilities (ARES).


An amount of DZD600 billion will be allocated to the rehabilitation of 15 large hospitals, spread"...

Continue Reading >